EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY-NC 4.0

Immunotherapy With Pembrolizumab for Resectable dMMR/MSI-H Stage III Colon Cancer: A Case of Personalized, Precision Surgery-Sparing Immunotherapy

Stanley Kim iD, Joseph I Clark

Journal of Investigative Medicine High Impact Case Reports · 2025-08 · 13

DOI: 10.1177/23247096251368093 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Journal of Investigative Medicine High Impact Case Reports, online erschienen am 22.08.2025. Verfasst von Stanley Kim und 1 weiteren Autor:innen. Beteiligte Einrichtung: MacNeal Cancer Center, Loyola University Chicago Stritch School od Medicine, Berwyn, IL, USA. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Colonic Neoplasms, Adenocarcinoma, Antineoplastic Agents, Immunological. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Colorectal cancer (CRC) with deficient mismatch repair (dMMR) and microsatellite instability-high (MSI-H) status represents a highly immunogenic subset that responds well to immune checkpoint inhibitors (ICIs). However, the role of ICIs in resectable, early-stage CRC remains under investigation. We report the case of an 81-year-old woman diagnosed with stage III adenocarcinoma of the right colon, who declined surgery. Immunohistochemistry revealed loss of MLH1 and PMS2, consistent with dMMR. Tumor genomic profiling demonstrated MSI-H, high tumor mutational burden, BRAF V600E, and BRCA2 mutation. Germline testing was negative for BRCA and Lynch syndrome-associated mutations. The patient was treated with neoadjuvant pembrolizumab. After 4 months, mesenteric lymphadenopathy resolved, but focal colonic thickening persisted. The patient again declined surgery. At 10 months of pembrolizumab therapy, PET/computed tomography and colonoscopy showed no residual disease. She developed immune-related adrenal insufficiency, managed with corticosteroids. This case demonstrates complete clinical remission of resectable colon cancer with pembrolizumab alone in a patient with somatic dMMR/MSI-H, BRAF V600E, and BRCA2 mutations. It supports the hypothesis that early use of ICIs—prior to metastatic progression and immune escape—may enhance efficacy. This report highlights the potential for personalized, surgery-sparing treatment strategies in genomically selected CRC patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedColonic NeoplasmsAdenocarcinomaAntineoplastic Agents, ImmunologicalImmunotherapyHumansFemaleAged, 80 and overMicrosatellite InstabilityDNA Mismatch RepairPrecision MedicineNeoplasm StagingProto-Oncogene Proteins B-raf

Stichwörter der Autor:innen

dMMR/MSI-H colon cancerimmunotherapypembrolizumabpersonalized oncologyprecision oncologysurgery-sparing immunotherapy

Substanzen

pembrolizumabAntibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicalProto-Oncogene Proteins B-raf

Autor:innen und Institutionen

  • MacNeal Cancer Center, Loyola University Chicago Stritch School od Medicine, Berwyn, IL, USA.
  • Cardinal Bernadin Cancer Center, Loyola University Chicago Stritch School of Medicine Maywood, IL, USA.

ORCID-Profile: Stanley Kim

Zitieren

APA

Kim, S., & Clark, J. I. (2025). Immunotherapy With Pembrolizumab for Resectable dMMR/MSI-H Stage III Colon Cancer: A Case of Personalized, Precision Surgery-Sparing Immunotherapy. Journal of Investigative Medicine High Impact Case Reports, 13. https://doi.org/10.1177/23247096251368093

Vancouver

Kim S, Clark JI. Immunotherapy With Pembrolizumab for Resectable dMMR/MSI-H Stage III Colon Cancer: A Case of Personalized, Precision Surgery-Sparing Immunotherapy. Journal of Investigative Medicine High Impact Case Reports. 2025;13. doi:10.1177/23247096251368093

BibTeX
@article{Kim2025,
  author = {Kim, Stanley and Clark, Joseph I},
  title = {Immunotherapy With Pembrolizumab for Resectable dMMR/MSI-H Stage III Colon Cancer: A Case of Personalized, Precision Surgery-Sparing Immunotherapy},
  journal = {Journal of Investigative Medicine High Impact Case Reports},
  year = {2025},
  volume = {13},
  doi = {10.1177/23247096251368093}
}
Kostenlos starten →